Navigation Links
Genzyme Announces Results of Clinical Trials Investigating Powder,Form of Sevelamer Carbonate

company has grown from a small start-up to a diversified enterprise with more than 9,000 employees in locations spanning the globe and 2006 revenues of $3.2 billion. Genzyme has been selected by FORTUNE as one of the “100 Best Companies to Work for” in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

Genzyme® and Renagel® are registered trademarks and RenvelaTM is a trademark of Genzyme Corporation. All rights reserved.

This press release contains forward-looking statements including, without limitation, statements about the development of Renvela™ for chronic kidney disease and alternative dosing regimens for the powder formulation of Renvela™. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others: additional analysis of the data comparing the powder form of Renvela™ to Renagel®; the results of other studies and whether such results are consistent with this data; the actual efficacy and safety of Renvela™ for chronic kidney disease; the outcome of discussions with regulatory authorities regarding clinical studies and the approval of Renvela™ for chronic kidney disease and the timing of such discussions; the timing and content of submissions to and decisions made by regulatory authorities; the availability and extent of third
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:1/23/2015)... EAST SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology ... sites where its Phase I trial of Lixte,s lead compound, ... 5 institutions. John S. Kovach , M.D., ... trial was planned to be completed at a single site. ...
(Date:1/23/2015)... CAPE TOWN, South Africa , Jan. 23, 2015 ... and distributor of personal protective equipment for all forms ... include the flagship Leatt-Brace® neck brace, announced today that ... minicross racing federation, now requires all riders to wear ...
(Date:1/23/2015)... Jan. 23, 2015  Mallinckrodt plc (NYSE: MNK ... approved a share repurchase program. The open-ended authorization permits ... Mallinckrodt plc ordinary shares. "Funding additional ... priorities as we continue to pursue a range of ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... HAMBURG, Germany, Sept. 20, 2011 Weight and height, ... leader for medical measuring and weighing. Now the company ... system integrating modern medical practices and hospital equipment. The ... problems of precise data capture, transmission and interpretation of ...
... Sept. 20, 2011 Valeant Pharmaceuticals International, Inc. ... existing senior secured credit facilities of its wholly ... facilities are guaranteed by the Company.  The proposed ... to consist of a $200 million revolving facility ...
Cached Medicine Technology:seca 360 wireless - The New Era of Measuring and Weighing 2Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities 2
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... Weddingshe.com has added many trendy Champagne wedding dresses ... in the past three years. Today, the business announces a ... to the sales manager of the company, this is on ... This point can be reflected on the discounted wedding dresses ...
(Date:1/22/2015)... 2015 Four years since the release of their ... with the marriage of Avasa & Matthew Love – the duo ... scheduled for release through White Swan Records on February 24, 2015. ... a sacred path available to all of us to walk out ...
(Date:1/22/2015)... IPSWICH, Mass. (PRWEB) January 22, 2015 ... Association (AMA) are expanding their relationship in an effort ... journals around the world. While EBSCO has long made AMA ... as a sales agent for The JAMA Network. ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for wedding ... its latest collection of wedding dresses , and launches a ... the wedding dress on your big day; the wedding gown ... bride wants to find the most suitable wedding dress. Now, ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... Aug. 15 ( http://www.amdl.com ),AMDL Inc. (Amex: ... pharmaceuticals with,operations in Shenzhen, Jiangxi and Jilin China, ... chief financial officer Akio Ariura will,host a teleconference ... The call is scheduled for Tuesday, August 19, ...
... Neuroblastoma is one of the most devastating diagnoses a ... old when the disease is detected, most often by ... By then, the disease has often reached an advanced ... of the children in whom it develops, despite aggressive ...
... a,statement of Betsy Ryan, President and CEO, New ... today submitted an application to the,state to convert ... for-profit,company., All New Jerseyans should be concerned ... 2.9 million members, Horizon is the largest,provider of ...
... Aug. 15 The Hereditary Disease Foundation,(HDF) is ... has,approved Xenazine, or tetrabenazine, for the treatment of ... major cause of disability and death in patients ... inconvenience; it can,prevent Huntington,s disease patients from walking, ...
... Organizations Come Together to Promote Health Care Reform as the ... Priority for the Next President and Congress, WASHINGTON, Aug. ... to defeat health care reform in 1993-1994, will be back ... top of the,agenda., Airing throughout the Democratic and Republican ...
... spent more than a few sleepless nights, you,re not ... over 55 -- but you may also be at ... older adults don,t get enough restorative sleep, leading to ... problems and increased rates of depression. Unfortunately, current sleeping ...
Cached Medicine News:Health News:AMDL Announces Teleconference to Discuss Its Second Quarter 2008 Financial Results 2Health News:Experiments could lead to new treatments for neuroblastoma 2Health News:Experiments could lead to new treatments for neuroblastoma 3Health News:NJHA Raises Questions Regarding Horizon's Proposal to Convert to For-Profit Health Insurer 2Health News:'Harry and Louise' Icons Return To Promote Health Care Reform In New Ad 2Health News:A therapy for baby boomers to sleep on 2
Passive heat and moisture exchangers for respiratory applications....
Ballard trach care HMES and filters, tv 500, HME...
... Thermovent® T helps provide protection to the exposed ... and extremely lightweight making it ideal for active ... high rate of heat and moisture recovery, it ... ,All HMEs and filters have ISO standard tapered ...
For use with: , pulmonary function testing , nebulizer compressors , humidifiers , concentrators , proximal pressure lines ...
Medicine Products: